论文部分内容阅读
目的:评价替加环素与头孢哌酮-舒巴坦对多重耐药鲍曼不动杆菌肺部感染患者的疗效及其对炎症因子的影响。方法:选取2016年1月—2017年1月间收治的多重耐药鲍曼不动杆菌肺部感染患者120例临床资料,根据患者用药方案的不同将其分为单用组(n=60)和联合组(n=60);单用组患者给予头孢哌酮-舒巴坦治疗,联合组患者在对照组基础上加用替加环素治疗,评价两组患者治疗后的总有效率、转阴率及其治疗前后炎症因子的变化情况。结果:联合组患者治疗后的总有效率、多重耐药鲍曼不动杆菌转阴率高于单用组(P<0.05),治疗后WBC、CRP、PCT测得值低于治疗前(P<0.05);联合组患者治疗后WBC、CRP、PCT测得值低于单用组(P<0.05);两组患者用药期间不良反应的发生率经组间比较其差异无统计学意义(P>0.05)。结论:采用替加环素与头孢哌酮-舒巴坦联用治疗多重耐药鲍曼不动杆菌肺部感染患者的疗效明显,改善了炎症因子水平。
Objective: To evaluate the curative effect of tigecycline and cefoperazone-sulbactam on patients with multi-drug resistant Acinetobacter baumannii pneumonia and its effect on inflammatory factors. Methods: A total of 120 patients with multi-drug resistant Acinetobacter baumannii infection in our hospital from January 2016 to January 2017 were enrolled in this study. Patients were divided into single use group (n = 60) And the combination group (n = 60). Patients in the single group were treated with cefoperazone-sulbactam. Patients in the combination group were treated with tigecycline on the basis of the control group, and the total effective rate after treatment was evaluated. Negative rate and its changes before and after treatment of inflammatory cytokines. Results: The total effective rate and Acinetobacter baumannii negative rate in combined group were higher than those in single group (P <0.05). The measured values of WBC, CRP and PCT after treatment were lower than those before treatment (P <0.05). The WBC, CRP and PCT values in the combined group were lower than those in the single group (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups > 0.05). Conclusion: The combination of tigecycline and cefoperazone-sulbactam in the treatment of multi-drug resistant Acinetobacter baumannii infection in patients with lung infection significantly improved the level of inflammatory cytokines.